STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today ...

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company’s clinical-stage programs consist of a ...

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that it has ...

Strasbourg (France), Tokyo (Japan) and Waltham, Mass, Mar 5, 2024 - (JCN Newswire) - - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the ...

Reaffirms potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent currently in a Phase I/IIa trial STRASBOURG, France--(BUSINESS WIRE)-- Regulatory News: Transgene (Euronext ...

TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer setting Financial visibility confirmed into Q4 2025 Strasbourg, ...

Strasbourg, France, January 23, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced ...

Authors: C. Lebbe, R. Bahleda, E. Ezine, B. Baroudjian, M. Sakkal, E. Rowinski, A. Vinceneux, S. Champiat, K. Bidet Huang, N. Stojkowitz, H. Makhloufi, A. Sadoun, A ...

Strasbourg, France, February 4, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG) a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, ...

Intra-tumoral BT-001 injection in combination with IV pembrolizumab was well tolerated with a manageable safety profile. Tumor shrinkage was observed in both injected and non-injected lesions. BT-001 ...